Stock Earnings

Question 1

TScan Therapeutics Incの主要な財務諸表は何ですか？

Accepted Answer

最新の財務諸表（Form-10K）によると、TScan Therapeutics Incの総資産は$371で、純lossは$-127です。

Question 2

TCRXの主要な財務比率は何ですか？

Accepted Answer

TScan Therapeutics Incの流動比率は2.85、純利益率は-6,350、1株当たり売上高は$0.01です。

Question 3

TScan Therapeutics Incの収益はセグメントまたは地域別にどのように分けられていますか？

Accepted Answer

TScan Therapeutics Inc largest revenue segment is T Cell Receptor-engineered T Cell, at a revenue of 2,816,000 in the most earnings release.For geography, United States is the primary market for TScan Therapeutics Inc, at a revenue of 2,816,000.

Question 4

TScan Therapeutics Incは収益を上げていますか？

Accepted Answer

no、最新の財務諸表によると、TScan Therapeutics Incの純lossは$-127です。

Question 5

TScan Therapeutics Incに負債はありますか？

Accepted Answer

yes、TScan Therapeutics Incの負債は130です。

Question 6

TScan Therapeutics Incの発行済株式数は何株ですか？

Accepted Answer

TScan Therapeutics Incの総発行済株式数は56.59株です。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	6	2	21	13	10	1
Revenue Growth (YoY)	-50%	-90%	62%	30%	900%	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	32	30	26	20	13	6
Research & Development	117	107	88	59	44	20
Operating Expenses	152	137	114	80	58	27
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-136	-127	-89	-66	-48	-26
Income Tax Expense	--	--	--	--	--	--
Net Income	-136	-127	-89	-66	-48	-26
Net Income Growth	31%	43%	35%	38%	85%	100%
Shares Outstanding (Diluted)	129.73	111.99	65.59	24.05	23.59	23.59
Shares Change (YoY)	14%	71%	173%	2%	0%	0%
EPS (Diluted)	-1.05	-1.13	-1.36	-2.75	-2.06	-1.11
EPS Growth	14%	-16%	-51%	34%	86%	91%
Free Cash Flow	-131	-114	-64	-70	-58	-7
Free Cash Flow Per Share	-1	-1.01	-0.97	-2.91	-2.45	-0.29
Gross Margin	--	--	--	--	--	--
Operating Margin	-2,416.66%	-6,700%	-442.85%	-507.69%	-480%	-2,600%
Profit Margin	-2,266.66%	-6,350%	-423.8%	-507.69%	-480%	-2,600%
Free Cash Flow Margin	-2,183.33%	-5,700%	-304.76%	-538.46%	-580%	-700%
EBITDA	-142	-130	-88	-61	-45	-25
EBITDA Margin	-2,366.66%	-6,500%	-419.04%	-469.23%	-450%	-2,500%
D&A For EBITDA	3	4	5	5	3	1
EBIT	-145	-134	-93	-66	-48	-26
EBIT Margin	-2,416.66%	-6,700%	-442.85%	-507.69%	-480%	-2,600%
Effective Tax Rate	--	--	--	--	--	--

TScan Therapeutics Inc (TCRX) Price

TCRX Stock Price Chart

TCRX Income

Follow-Up Questions